AKT1 and Alzheimer disease: Glycogen synthase kinase 3 (GSK-3) is a downstream target of the PI3K/AKT signaling pathway, which is considered to play a key role in AD pathology such as tau phosphorylation, Aβ aggregation, memory deficit, neurogenesis, and synaptic dysfunction [31, 32].